Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Uncovering molecular markers of the microvascular endothelial response in sepsis-associated acute kidney injury: a translational study in mice and humans.

Intensive care medicine experimental·2025
Same author

Cord blood levels of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 correlate with perinatal brain development in fetal congenital heart disease.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

Potentially modifiable ventilation factors associated with outcome in neurocritical care vs. non-neurocritical care patients: Rational and protocol for a patient-level analysis of PRoVENT, PRoVENT-iMiC and ENIO (PRIME).

Revista espanola de anestesiologia y reanimacion..·2025
Same author

Hospital to home transition of children with medical complexities in the Netherlands: current practice.

European journal of pediatrics·2025
Same author

Risk factors for PPCs in laparoscopic non-robotic vs. laparoscopic robotic abdominal surgery (LapRas): rationale and protocol for a patient-level analysis of LAS VEGAS and AVATaR.

Revista espanola de anestesiologia y reanimacion·2024
Same author

Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection.

The Journal of infectious diseases·2023

Related Experiment Video

Updated: Jun 3, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

Liposome-encapsulated dexamethasone attenuates ventilator-induced lung inflammation.

M A Hegeman1, P M Cobelens, Jaam Kamps

  • 1Laboratory of Neuroimmunology and Developmental Origins of Disease, Utrecht, the Netherlands.

British Journal of Pharmacology
|March 12, 2011
PubMed
Summary

Targeting liposomes with immunoglobulin G (IgG) improved dexamethasone delivery to the lungs, effectively reducing ventilator-induced lung inflammation and granulocyte infiltration. This targeted approach offers a promising alternative to systemic glucocorticoid therapy.

More Related Videos

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

Related Experiment Videos

Last Updated: Jun 3, 2026

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
09:36

Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device

Published on: September 24, 2020

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury
08:27

Bronchoalveolar Lavage Exosomes in Lipopolysaccharide-induced Septic Lung Injury

Published on: May 21, 2018

Area of Science:

  • Pulmonary Medicine
  • Nanotechnology in Drug Delivery
  • Immunology

Background:

  • Systemic glucocorticoids treat lung inflammation but cause side effects.
  • Liposomal drug delivery offers localized treatment potential.
  • Targeting Fcγ-receptors (FcγRs) may enhance liposome efficacy.

Purpose of the Study:

  • To investigate if liposome-encapsulated dexamethasone inhibits ventilator-induced lung inflammation.
  • To evaluate if FcγR-targeted liposomes improve dexamethasone efficacy in reducing granulocyte infiltration.

Main Methods:

  • Mice were mechanically ventilated with low (LV(T)) or high (HV(T)) tidal volumes.
  • Intravenous administration of dexamethasone-liposomes (Dex-liposomes), IgG-modified dexamethasone-liposomes (IgG-Dex-liposomes), or free dexamethasone.
  • Assessment of granulocyte infiltration and inflammatory mediator mRNA expression.

Main Results:

  • Dex-liposomes attenuated inflammation in LV(T) but not HV(T) ventilation.
  • IgG-Dex-liposomes significantly inhibited granulocyte influx in both LV(T) and HV(T) groups.
  • Free dexamethasone also prevented inflammation; IgG-Dex-liposomes showed comparable efficacy with localized delivery.

Conclusions:

  • FcγR-targeted IgG-Dex-liposomes are more effective than non-targeted liposomes for inhibiting lung inflammation.
  • IgG-Dex-liposomes provide localized lung delivery, potentially minimizing systemic side effects.
  • Targeted liposomal dexamethasone demonstrates significant therapeutic potential for ventilator-induced lung injury.